Home
>
US Stocks
>
Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals, Inc. (DCPH)

$13.5

-0.1

(-0.74%)▲

Market is closed - opens 7 PM, 01 Jun 2023

Insights on Deciphera Pharmaceuticals, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 36.34M → 33.44M (in $), with an average decrease of 8.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -43.04M → -45.96M (in $), with an average decrease of 3.4% per quarter

  • Vs ZTS

    In the last 3 years, Deciphera Pharmaceuticals Inc has experienced a drawdown of -76.8%, however Zoetis Inc - Class A resisted the overall trend and outperformed by 49.0%

Performance

  • $13.39
    $14.20
    $13.50
    downward going graph

    0.81%

    Downside

    Day's Volatility :5.7%

    Upside

    4.93%

    downward going graph
  • $10.14
    $22.76
    $13.50
    downward going graph

    24.89%

    Downside

    52 Weeks Volatility :55.45%

    Upside

    40.69%

    downward going graph

Returns

PeriodDeciphera Pharmaceuticals, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-6.21%
-0.3%
-6.7%
6 Months
-14.52%
-8.8%
-6.2%
1 Year
25.46%
-4.2%
-5.1%
3 Years
-77.59%
23.0%
26.9%

Highlights

Market Capitalization
1.1B
Book Value
$5.61
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.07
Wall Street Target Price
21.33
Profit Margin
-131.38%
Operating Margin TTM
-136.76%
Return On Assets TTM
-25.29%
Return On Equity TTM
-51.05%
Revenue TTM
138.3M
Revenue Per Share TTM
1.7
Quarterly Revenue Growth YOY
14.399999999999999%
Gross Profit TTM
-62.6M
EBITDA
-186.3M
Diluted Eps TTM
-2.07
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.46
EPS Estimate Next Year
-2.04
EPS Estimate Current Quarter
-0.59
EPS Estimate Next Quarter
-0.58

Analyst Recommendation

Buy
    64%Buy
    29%Hold
    5%Sell
Based on 17 Wall street analysts offering stock ratings for Deciphera Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
5
5
5
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 58.0%

Current $13.50
Target $21.33

Technicals Summary

Sell

Neutral

Buy

Deciphera Pharmaceuticals, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Deciphera Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, Inc.
-6.01%
-14.52%
25.46%
-77.59%
-47.12%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-13.37%
-29.08%
-3.62%
-26.98%
-6.39%
Zoetis Inc.
Zoetis Inc.
-10.37%
4.41%
-5.84%
16.34%
92.28%
Viatris Inc.
Viatris Inc.
-1.92%
-16.77%
-25.18%
-43.82%
-43.82%
Catalent, Inc.
Catalent, Inc.
-27.33%
-27.35%
-64.66%
-52.48%
-7.23%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Deciphera Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, Inc.
NA
NA
NA
-2.46
-0.51
-0.25
0.0
5.61
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
147.13
147.13
1.87
2.1
0.04
0.08
0.0
17.28
Zoetis Inc.
Zoetis Inc.
37.27
37.27
3.53
5.4
0.45
0.13
0.01
9.72
Viatris Inc.
Viatris Inc.
5.82
5.82
NA
2.95
0.09
0.03
0.05
17.45
Catalent, Inc.
Catalent, Inc.
16.09
16.09
1.18
1.37
0.09
0.04
0.0
27.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Deciphera Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, Inc.
Buy
$1.1B
-47.12%
NA
-131.38%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$8.9B
-6.39%
147.13
4.0%
Zoetis Inc.
Zoetis Inc.
Buy
$76.1B
92.28%
37.27
25.59%
Viatris Inc.
Viatris Inc.
Hold
$10.9B
-43.82%
5.82
12.05%
Catalent, Inc.
Catalent, Inc.
Buy
$6.6B
-7.23%
16.09
8.62%

Institutional Holdings

  • Redmile Group, LLC

    7.11%

  • BlackRock Inc

    6.90%

  • Deerfield Management Co

    6.65%

  • Vanguard Group Inc

    5.87%

  • Armistice Capital, LLC

    5.22%

  • State Street Corporation

    4.23%

Corporate Announcements

  • Deciphera Pharmaceuticals, Inc. Earnings

    Deciphera Pharmaceuticals, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. The Company is leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from its platform in clinical studies, QINLOCK is Deciphera's FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Canada and Australia.

Organization
Deciphera Pharmaceuticals, Inc.
Employees
300
CEO
Mr. Steven L. Hoerter
Industry
Health Technology

Discover More

FAQs